产品简要
公司名称 :
ACROBiosystems
产品类型 :
蛋白
产品名称 :
ActiveMax® Human TGF-Beta 1 / TGFB1 Protein, Tag Free
目录 :
TG1-H4212
规格 :
50微克, 1毫克
价格 :
599美元, 3090美元
更多信息或购买 :
产品信息
公司名称 :
ACROBiosystems
产品类型 :
蛋白
目录 :
TG1-H4212
产品名称 :
ActiveMax® Human TGF-Beta 1 / TGFB1 Protein, Tag Free
规格 :
50微克, 1毫克
价格 :
599美元, 3090美元
规格&价格 :
$599/50ug,$3090/1mg (500ug × 2)
靶标 :
TGF乙1
宿主物种 :
人类
By Tag :
Tag Free
研究 :
For Research Use Only
来源 :
ActiveMax® Human TGFB1, Tag Free (TG1-H4212) is expressed from human 293 cells (HEK293). It contains AA Ala 279 - Ser 390 (Accession # P01137-1).
内毒素 :
Less than 1.0 EU per μg by the LAL method.
纯度 :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
ActiveMax® Human TGFB1, Tag Free on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
配方 :
Lyophilized from 0.22 μm filtered solution in 0.085% TFA in 30% ACN. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation. This product does not contains polyhis tag, but there exists extremely low level of polyhis tag which might interfere with your assay when using together with anti-his tag secondary antibody.
重组 :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
储存 :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: ● -20°C to -70°C for 12 months in lyophilized state; ● -70℃ for 12 months under sterile conditions after reconstitution.
背景 :
Transforming growth factor beta 1 ( TGFB1) is also known as TGF-β1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I and Decorin.
参考文献 :
(1) Ghadami M, et al., 2000, Am. J. Hum. Genet. 66 (1): 143–7. (2) Assoian R, et al., 1983, J Biol Chem , 258 (11): 7155–60. (3) Derynck R, et al., 1985, Nature 316 (6030): 701–5. (4) Letterio J, Roberts A, 1998, Annu Rev Immunol 16: 137–61.
更多信息或购买 :
公司信息
ACROBiosystems
1 Innovation Way Newark, DE 19711, USA
order@acrobiosystems.com
http://www.acrobiosystems.com
1-800-810-0816
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.

Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.

As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.

We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.